2019冠状病毒病体温轨迹与高炎症及高凝亚表型相关
该回顾性观察研究纳入4家医院2020年3月至2021年2月收治的5,903例成人COVID-19住院患者,用经验证的基于组的轨迹模型,依据入院前72小时口腔温度将患者分为4种体温轨迹亚表型:热缓降型(n=1,452,25%)、热快降型(n=1,469,25%)、正常体温型(n=2,126,36%)和低体温型(n=856,15%)。低体温型凝血标志物异常,D-二聚体和纤维蛋白单体最高(p<0.001),脑血管意外发生率最高(10%,p=0.001),静脉血栓栓塞发生率在亚表型间有显著差异(p=0.005),低体温型最高(8.5%),热缓降型最低(5.1%)。热缓降型炎症标志物异常,C反应蛋白、铁蛋白和白细胞介素-6最高(p<0.001)。与热快降型相比,热缓降型机械通气、血管升压药使用和30天住院死亡的比值比增加(OR 1.58;95%CI 1.13-2.19)。大流行期间热缓降型占比从2020年3月的53%降至2021年的不足15%;地塞米松使用与热缓降型归属概率显著降低相关(降低27%;95%CI 23-31%;p<0.001)。
要点
- 低体温型(n=856,15%)D-二聚体和纤维蛋白单体最高(p<0.001),脑血管意外发生率10%(p=0.001),静脉血栓栓塞发生率8.5%,提示高凝亚表型。
- 热缓降型(n=1,452,25%)C反应蛋白、铁蛋白和白细胞介素-6最高(p<0.001),提示高炎症亚表型。
- 与热快降型相比,热缓降型机械通气、血管升压药使用和30天住院死亡的OR为1.58(95%CI 1.13-2.19)。
- 静脉血栓栓塞发生率在4种亚表型间有显著差异(p=0.005),低体温型最高(8.5%),热缓降型最低(5.1%)。
- 地塞米松使用与热缓降型归属概率降低27%相关(95%CI 23-31%;p<0.001)。
适用人群与场景
- 2020年3月至2021年2月,学术医疗系统内4家医院收治的所有成人COVID-19住院患者。
诊断标准与关键阈值
- 使用经验证的基于组的轨迹模型,依据入院前72小时口腔温度测量值,将患者分为4种体温轨迹亚表型:热缓降型、热快降型、正常体温型、低体温型。
红旗征与不能漏的情况
- 低体温型凝血标志物异常(D-二聚体和纤维蛋白单体最高,p<0.001),脑血管意外发生率10%(p=0.001),静脉血栓栓塞发生率8.5%,需警惕高凝状态。
- 热缓降型炎症标志物最高(C反应蛋白、铁蛋白、白细胞介素-6,p<0.001),且机械通气、血管升压药使用和30天住院死亡风险更高。
研究设计与关键结果
- 回顾性观察研究,纳入4家医院5,903例成人COVID-19住院患者,分为热缓降型(n=1,452,25%)、热快降型(n=1,469,25%)、正常体温型(n=2,126,36%)、低体温型(n=856,15%)。
- 低体温型D-二聚体和纤维蛋白单体最高(p<0.001),脑血管意外发生率10%(p=0.001);静脉血栓栓塞发生率在亚表型间有显著差异(p=0.005),低体温型最高(8.5%),热缓降型最低(5.1%)。
- 热缓降型C反应蛋白、铁蛋白和白细胞介素-6最高(p<0.001)。
- 与热快降型相比,热缓降型机械通气、血管升压药使用和30天住院死亡的OR为1.58(95%CI 1.13-2.19)。
- 大流行期间热缓降型占比从2020年3月的53%降至2021年的不足15%。
- 地塞米松使用与热缓降型归属概率降低27%相关(95%CI 23-31%;p<0.001)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来应研究体温亚表型是否能从靶向抗血栓和抗炎策略中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Body temperature trajectories of infected patients are associated with specific immune profiles and survival. We determined the association between temperature trajectories and distinct manifestations of coronavirus disease 2019.
DESIGN: Retrospective observational study.
SETTING: Four hospitals within an academic healthcare system from March 2020 to February 2021.
PATIENTS: All adult patients hospitalized with coronavirus disease 2019.
INTERVENTIONS: Using a validated group-based trajectory model, we classified patients into four previously defined temperature trajectory subphenotypes using oral temperature measurements from the first 72 hours of hospitalization. Clinical characteristics, biomarkers, and outcomes were compared between subphenotypes.
MEASUREMENTS AND MAIN RESULTS: The 5,903 hospitalized coronavirus disease 2019 patients were classified into four subphenotypes: hyperthermic slow resolvers (n = 1,452, 25%), hyperthermic fast resolvers (1,469, 25%), normothermics (2,126, 36%), and hypothermics (856, 15%). Hypothermics had abnormal coagulation markers, with the highest d-dimer and fibrin monomers (p < 0.001) and the highest prevalence of cerebrovascular accidents (10%, p = 0.001). The prevalence of venous thromboembolism was significantly different between subphenotypes (p = 0.005), with the highest rate in hypothermics (8.5%) and lowest in hyperthermic slow resolvers (5.1%). Hyperthermic slow resolvers had abnormal inflammatory markers, with the highest C-reactive protein, ferritin, and interleukin-6 (p < 0.001). Hyperthermic slow resolvers had increased odds of mechanical ventilation, vasopressors, and 30-day inpatient mortality (odds ratio, 1.58; 95% CI, 1.13-2.19) compared with hyperthermic fast resolvers. Over the course of the pandemic, we observed a drastic decrease in the prevalence of hyperthermic slow resolvers, from representing 53% of admissions in March 2020 to less than 15% by 2021. We found that dexamethasone use was associated with significant reduction in probability of hyperthermic slow resolvers membership (27% reduction; 95% CI, 23-31%; p < 0.001).
CONCLUSIONS: Hypothermics had abnormal coagulation markers, suggesting a hypercoagulable subphenotype. Hyperthermic slow resolvers had elevated inflammatory markers and the highest odds of mortality, suggesting a hyperinflammatory subphenotype. Future work should investigate whether temperature subphenotypes benefit from targeted antithrombotic and anti-inflammatory strategies.
参考来源
- Bhavani SV, Verhoef PA, Maier CL, et al. Coronavirus Disease 2019 Temperature Trajectories Correlate With Hyperinflammatory and Hypercoagulable Subphenotypes. Crit Care Med. 2022. PMID: 35100194. doi:10.1097/CCM.0000000000005397
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。